A series of amino acid monoester prodrugs of floxuridine was synthesized and evaluated for the improvement of oral bioavailability and the feasibility of target drug delivery via oligopeptide transporters. All floxuridine 5'-amino acid monoester prodrugs exhibited PEPT1 affinity, with inhibition coefficients of Gly-Sar uptake (IC50) ranging from 0.7 - 2.3 mM in Caco-2 and 2.0 - 4.8 mM in AsPC-1 cells, while that of floxuridine was 7.3 mM and 6.3 mM, respectively. Caco-2 membrane permeabilities of floxuridine prodrugs (1.01 - 5.31 x 10(-6 )cm/sec) and floxuridine (0.48 x 10(-6 )cm/sec) were much higher than that of 5-FU (0.038 x 10(-6) cm/sec). MDCK cells stably transfected with the human oligopeptide transporter PEPT1 (MDCK/hPEPT1) exhibite...
Objectives. Peptide transporters have broad substrate specificity and could be a good target for che...
Objectives. Peptide transporters have broad substrate specificity and could be a good target for che...
One of the main obstacles for cancer therapies is to deliver medicines effectively to target sites. ...
A series of amino acid monoester prodrugs of floxuridine was synthesized and evaluated for the impro...
Floxuridine is a clinically proven anticancer agent in the treatment of metastatic colon carcinomas ...
Floxuridine is a clinically proven anticancer agent in the treatment of metastatic colon carcinomas ...
Purpose. The aim of this study was to synthesize amino acid ester prodrugs of 5-fluoro-2′-deoxyuridi...
The anticancer drug, floxuridine, exhibits poor oral bioavailability partially due to extensive firs...
The researches were conducted to determine the advantages of prodrug approach over a parent drug. 5'...
The researches were conducted to determine the advantages of prodrug approach over a parent drug. 5'...
The anticancer drug, floxuridine, exhibits poor oral bioavailability partially due to extensive firs...
The aim of this study was to synthesize amino acid ester prodrugs of 5-fluoro-2′-deoxyuridine (floxu...
Dipeptide monoester prodrugs of floxuridine and gemcitabine were synthesized. Their chemical stabili...
Dipeptide monoester prodrugs of floxuridine and gemcitabine were synthesized. Their chemical stabili...
Dipeptide monoester prodrugs of floxuridine and gemcitabine were synthesized. Their chemical stabili...
Objectives. Peptide transporters have broad substrate specificity and could be a good target for che...
Objectives. Peptide transporters have broad substrate specificity and could be a good target for che...
One of the main obstacles for cancer therapies is to deliver medicines effectively to target sites. ...
A series of amino acid monoester prodrugs of floxuridine was synthesized and evaluated for the impro...
Floxuridine is a clinically proven anticancer agent in the treatment of metastatic colon carcinomas ...
Floxuridine is a clinically proven anticancer agent in the treatment of metastatic colon carcinomas ...
Purpose. The aim of this study was to synthesize amino acid ester prodrugs of 5-fluoro-2′-deoxyuridi...
The anticancer drug, floxuridine, exhibits poor oral bioavailability partially due to extensive firs...
The researches were conducted to determine the advantages of prodrug approach over a parent drug. 5'...
The researches were conducted to determine the advantages of prodrug approach over a parent drug. 5'...
The anticancer drug, floxuridine, exhibits poor oral bioavailability partially due to extensive firs...
The aim of this study was to synthesize amino acid ester prodrugs of 5-fluoro-2′-deoxyuridine (floxu...
Dipeptide monoester prodrugs of floxuridine and gemcitabine were synthesized. Their chemical stabili...
Dipeptide monoester prodrugs of floxuridine and gemcitabine were synthesized. Their chemical stabili...
Dipeptide monoester prodrugs of floxuridine and gemcitabine were synthesized. Their chemical stabili...
Objectives. Peptide transporters have broad substrate specificity and could be a good target for che...
Objectives. Peptide transporters have broad substrate specificity and could be a good target for che...
One of the main obstacles for cancer therapies is to deliver medicines effectively to target sites. ...